CoChat

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

Open access
Takahashi, Nagahide, Yamada, Aya, Shiraishi, Ayako, Shimizu, Hiroko, Goto, Ryosuke, Tominaga, Yushin · 2021 · BMC Psychiatry

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Background: Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of esketamine nasal spray in Japanese patients with TRD needs to be assessed. Methods: This Phase 2b, randomized, double-blind (DB), placebo-controlled study was conducted in adult Japanese patients with TRD meeting the Diagnostic and Statistical Manual of Mental Disorders (fifth edition) criteria of major depressive disorder with nonresponse to ≥ 1 but < 5 different ADs in the current episode at screening. Patients were treated with a new oral AD for 6 weeks (prospective lead-in phase); nonresponders were randomized (2:1:1:1) to placebo or esketamine (28-, 56-, or 84-mg) nasal spray along with the continued use of AD for 4 weeks (DB induction phase). Responders (≥50% reduction from baseline in the Montgomery-Asberg Depression Rating Scale [MADRS] total score) from the DB induction phase continued into the 24-week posttreatment phase and patients who relapsed could participate in a 4-week open-label (OL) second induction (flexibly-dosed esketamine). The primary efficacy endpoint, change from baseline in the MADRS total score at Day 28 in the DB induction phase, was based on mixed-effects model using repeated measures pairwise comparisons using a Dunnett adjustment. Results: Of the 202 patients randomized in the DB induction phase (esketamine [n = 122] or placebo [n = 80]), the MADRS total scores decreased from baseline to Day 28 of the DB induction phase (− 15.2, − 14.5, − 15.1, and − 15.3 for esketamine 28 mg, 56 mg, 84 mg, and placebo groups, respectively), indicating an improvement in depressive symptoms; however, the difference between the esketamine and placebo groups was not statistically significant. The most common treatment-emergent adverse events during the DB induction phase in the combined esketamine group (incidences ranging from 12.3 to 41.0%) were blood pressure increased, dissociation, dizziness, somnolence, nausea, hypoaesthesia, vertigo, and headache; the incidence of each of these events was > 2-fold higher than the corresponding incidence in the placebo group. Conclusions: Efficacy of esketamine plus oral AD in Japanese TRD patients was not established; further investigation is warranted. All esketamine doses were safe and tolerated. Trial registration: ClinicalTrials.gov Identifier: NCT02918318. Registered: 28 September 2016.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-021-03538-y

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patient Disposition. Notes: In the DB follow-up phase and posttreatment phase, the dose groups are the ones randomized during the DB induction phase. *The patients received only oral AD medication during the DB follow-up phase, posttreatment phase, and OL follow-up phase. Abbreviations: AD = antidepressant; AE = adverse event; COM = completed; DB = double-blind; Esk = esketamine; Flex = flexible; LFU = lost to follow-up; LOE = loss of efficacy; N = number of patients; NC = noncompliance; OL = open-label; OTH = other reason for withdrawal; PLO = placebo; WBP = withdrawal by patient; WDDB = withdrawal from DB induction phase; WDDBFU = withdrawal from DB follow-up phase; WDOL = withdrawal from OL induction phase; WDOLFU = withdrawal from OL follow-up phase; WDPT = withdrawal from posttreatment phase
Fig. 1 Patient Disposition. Notes: In the DB follow-up phase and posttreatment phase, the dose groups are the ones randomized during the DB induction phase. *The patients received only oral AD medication during the DB follow-up phase, posttreatment phase, and OL follow-up phase. Abbreviations: AD = antidepressant; AE = adverse event; COM = completed; DB = double-blind; Esk = esketamine; Flex = flexible; LFU = lost to follow-up; LOE = loss of efficacy; N = number of patients; NC = noncompliance; OL = open-label; OTH = other reason for withdrawal; PLO = placebo; WBP = withdrawal by patient; WDDB = withdrawal from DB induction phase; WDDBFU = withdrawal from DB follow-up phase; WDOL = withdrawal from OL induction phase; WDOLFU = withdrawal from OL follow-up phase; WDPT = withdrawal from posttreatment phaseCC BY · PubMed Central
Fig. 2 Mean Change in MADRS Total Score Over Time Observed Case MMRM; DB Induction Phase. Abbreviations: DB = double-blind; Esk = esketamine; MADRS = Montgomery-Asberg Depression Rating Scale; MMRM = mixed-model for repeated measures; SE = standard error
Fig. 2 Mean Change in MADRS Total Score Over Time Observed Case MMRM; DB Induction Phase. Abbreviations: DB = double-blind; Esk = esketamine; MADRS = Montgomery-Asberg Depression Rating Scale; MMRM = mixed-model for repeated measures; SE = standard errorCC BY · PubMed Central
Fig. 3 CGI-S Score Over Time; DB Induction Phase. Abbreviations: CGI-S=Clinical Global Impression-Severity; DB = double-blind; Esk = esketamine
Fig. 3 CGI-S Score Over Time; DB Induction Phase. Abbreviations: CGI-S=Clinical Global Impression-Severity; DB = double-blind; Esk = esketamineCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 5

  1. Guy W. ECDEU assessment manual for psychopharmacology revised. US Department of Health, education, and welfare publication (ADM). Rockville: National Institute of Mental Health; 1976.
  2. Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder - Superiority study of 40mg and 60mg versus 5mg. Jpn J Clin Psychopharmacol. 2009;12:1595–612 (in Japanese with English-language abstract).
  3. Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder - Placebo- and paroxetine-controlled double-blind comparative study. Jpn J Clin Psychopharmacol. 2009;12:1613–34 (in Japanese with English-language abstract).
  4. Hirayasu Y, Sato H. A dose-response study of escitalopram in patients with major depressive disorder: a placebo-controlled, double-blind study. Jpn J Clin Psychopharmacol. 2011;14:871–82 (in Japanese with English-language abstract).
  5. Hirayasu Y. A dose-response and non-inferiority study evaluating the efficacy and safety of escitalopram in patients with major depressive disorder: a placebo- and paroxetine-controlled, double-blind, comparative study. Jpn J Clin Psychopharmacol. 2011;14:883–99 (in Japanese with English-language abstract).

Cited by

See all 64

Metadata

Authors
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y.
Affiliations
  • Nagoya University (JP)
  • Janssen Pharmaceutical K.K. (Japan) (JP)
Corresponding author
Tominaga, Yushin
Venue
BMC Psychiatry
Published
2021-10-25
Volume
21
Issue
1
Pages
526-526
ISSN
1471-244X (ISSN-L)
OpenAlex
W3208279447
Cited by
57
References
39
Citations by year
2026: 4 · 2025: 20 · 2024: 9 · 2023: 14 · 2022: 10
FWCI
4.82
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine, intranasal administration, treatment-resistant depression, major depressive disorder, adjunctive therapy, oral antidepressant, Japanese patients, dose-response relationship, tolerability, adverse events, blood pressure increase, dissociation, relapse, flexible dosing, antidepressant non-response, ketamine analogues, NMDA receptor antagonists
MeSH terms
Adult, Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Humans, Japan, Ketamine, Prospective Studies, Treatment Outcome, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. https://app.cochat.ai/papers/10.1186/s12888-021-03538-y
The paper
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021). Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC Psychiatry. https://doi.org/10.1186/s12888-021-03538-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.